Follow-up after systemic adverse reactions of immunotherapy
Out of 280 immunotherapy (IT)-treated patients in our allergy clinic, 37 (13%) developed systemic adverse reactions. Parietaria judaica (Pj) extract, a highly allergenic pollen in northern Israel, was part of the IT regimen in 46% of treated patients who developed systemic adverse reactions. Twenty-...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Toubi, E [verfasserIn] Kessel, A [verfasserIn] Blant, A [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Copenhagen: Munksgaard International Publishers ; 1999 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2002 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: Allergy - Oxford : Blackwell Munksgaard, 1978, 54(1999), 6, Seite 0 |
| Übergeordnetes Werk: |
volume:54 ; year:1999 ; number:6 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1034/j.1398-9995.1999.t01-1-00094.x |
|---|
| Katalog-ID: |
NLEJ242307450 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242307450 | ||
| 003 | DE-627 | ||
| 005 | 20210707153117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s1999 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1034/j.1398-9995.1999.t01-1-00094.x |2 doi | |
| 035 | |a (DE-627)NLEJ242307450 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Toubi, E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Follow-up after systemic adverse reactions of immunotherapy |
| 264 | 1 | |a Copenhagen |b Munksgaard International Publishers |c 1999 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Out of 280 immunotherapy (IT)-treated patients in our allergy clinic, 37 (13%) developed systemic adverse reactions. Parietaria judaica (Pj) extract, a highly allergenic pollen in northern Israel, was part of the IT regimen in 46% of treated patients who developed systemic adverse reactions. Twenty-six (70%) of systemic adverse reactions occurred during the buildup phase, whereas 11 (30%) occurred in the maintenance phase of treatment. Mild systemic reactions developed in 15/37 (40%), moderate in 20/37 (54%), and severe in 2/37 (5%) of patients. In 22/37 (59% of our IT-treated patients, adverse reactions developed within 30 min after injection. Among these were the two patients with severe systemic reactions. In 19%, moderate adverse reactions appeared at 30–60 min; in 22%, mild to moderate reactions appeared after 1–2 h. Our study concludes that severe systemic reactions to IT usually appear within 30 min after injection. In Israel, IT with highly allergenic pollens such as Pj frequently causes systemic reactions, even during the maintenance phase of treatment. In such cases, the reduction of IT dosage should be more than 50% during the pollen season, and a waiting period of 1 h should also be considered. | ||
| 533 | |d 2002 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2002|||||||||| | ||
| 650 | 4 | |a buildup phase | |
| 700 | 1 | |a Kessel, A |e verfasserin |4 aut | |
| 700 | 1 | |a Blant, A |e verfasserin |4 aut | |
| 700 | 1 | |a Golan, TD |4 oth | |
| 773 | 0 | 8 | |i In |t Allergy |d Oxford : Blackwell Munksgaard, 1978 |g 54(1999), 6, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243926979 |w (DE-600)2003114-2 |x 1398-9995 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:1999 |g number:6 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1034/j.1398-9995.1999.t01-1-00094.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 1999 |e 6 |h 0 | ||
| author_variant |
e t et a k ak a b ab |
|---|---|
| matchkey_str |
article:13989995:1999----::olwpfesseiavreecino |
| hierarchy_sort_str |
1999 |
| publishDate |
1999 |
| allfields |
10.1034/j.1398-9995.1999.t01-1-00094.x doi (DE-627)NLEJ242307450 DE-627 ger DE-627 rakwb Toubi, E verfasserin aut Follow-up after systemic adverse reactions of immunotherapy Copenhagen Munksgaard International Publishers 1999 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Out of 280 immunotherapy (IT)-treated patients in our allergy clinic, 37 (13%) developed systemic adverse reactions. Parietaria judaica (Pj) extract, a highly allergenic pollen in northern Israel, was part of the IT regimen in 46% of treated patients who developed systemic adverse reactions. Twenty-six (70%) of systemic adverse reactions occurred during the buildup phase, whereas 11 (30%) occurred in the maintenance phase of treatment. Mild systemic reactions developed in 15/37 (40%), moderate in 20/37 (54%), and severe in 2/37 (5%) of patients. In 22/37 (59% of our IT-treated patients, adverse reactions developed within 30 min after injection. Among these were the two patients with severe systemic reactions. In 19%, moderate adverse reactions appeared at 30–60 min; in 22%, mild to moderate reactions appeared after 1–2 h. Our study concludes that severe systemic reactions to IT usually appear within 30 min after injection. In Israel, IT with highly allergenic pollens such as Pj frequently causes systemic reactions, even during the maintenance phase of treatment. In such cases, the reduction of IT dosage should be more than 50% during the pollen season, and a waiting period of 1 h should also be considered. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| buildup phase Kessel, A verfasserin aut Blant, A verfasserin aut Golan, TD oth In Allergy Oxford : Blackwell Munksgaard, 1978 54(1999), 6, Seite 0 Online-Ressource (DE-627)NLEJ243926979 (DE-600)2003114-2 1398-9995 nnns volume:54 year:1999 number:6 pages:0 http://dx.doi.org/10.1034/j.1398-9995.1999.t01-1-00094.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 54 1999 6 0 |
| spelling |
10.1034/j.1398-9995.1999.t01-1-00094.x doi (DE-627)NLEJ242307450 DE-627 ger DE-627 rakwb Toubi, E verfasserin aut Follow-up after systemic adverse reactions of immunotherapy Copenhagen Munksgaard International Publishers 1999 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Out of 280 immunotherapy (IT)-treated patients in our allergy clinic, 37 (13%) developed systemic adverse reactions. Parietaria judaica (Pj) extract, a highly allergenic pollen in northern Israel, was part of the IT regimen in 46% of treated patients who developed systemic adverse reactions. Twenty-six (70%) of systemic adverse reactions occurred during the buildup phase, whereas 11 (30%) occurred in the maintenance phase of treatment. Mild systemic reactions developed in 15/37 (40%), moderate in 20/37 (54%), and severe in 2/37 (5%) of patients. In 22/37 (59% of our IT-treated patients, adverse reactions developed within 30 min after injection. Among these were the two patients with severe systemic reactions. In 19%, moderate adverse reactions appeared at 30–60 min; in 22%, mild to moderate reactions appeared after 1–2 h. Our study concludes that severe systemic reactions to IT usually appear within 30 min after injection. In Israel, IT with highly allergenic pollens such as Pj frequently causes systemic reactions, even during the maintenance phase of treatment. In such cases, the reduction of IT dosage should be more than 50% during the pollen season, and a waiting period of 1 h should also be considered. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| buildup phase Kessel, A verfasserin aut Blant, A verfasserin aut Golan, TD oth In Allergy Oxford : Blackwell Munksgaard, 1978 54(1999), 6, Seite 0 Online-Ressource (DE-627)NLEJ243926979 (DE-600)2003114-2 1398-9995 nnns volume:54 year:1999 number:6 pages:0 http://dx.doi.org/10.1034/j.1398-9995.1999.t01-1-00094.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 54 1999 6 0 |
| allfields_unstemmed |
10.1034/j.1398-9995.1999.t01-1-00094.x doi (DE-627)NLEJ242307450 DE-627 ger DE-627 rakwb Toubi, E verfasserin aut Follow-up after systemic adverse reactions of immunotherapy Copenhagen Munksgaard International Publishers 1999 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Out of 280 immunotherapy (IT)-treated patients in our allergy clinic, 37 (13%) developed systemic adverse reactions. Parietaria judaica (Pj) extract, a highly allergenic pollen in northern Israel, was part of the IT regimen in 46% of treated patients who developed systemic adverse reactions. Twenty-six (70%) of systemic adverse reactions occurred during the buildup phase, whereas 11 (30%) occurred in the maintenance phase of treatment. Mild systemic reactions developed in 15/37 (40%), moderate in 20/37 (54%), and severe in 2/37 (5%) of patients. In 22/37 (59% of our IT-treated patients, adverse reactions developed within 30 min after injection. Among these were the two patients with severe systemic reactions. In 19%, moderate adverse reactions appeared at 30–60 min; in 22%, mild to moderate reactions appeared after 1–2 h. Our study concludes that severe systemic reactions to IT usually appear within 30 min after injection. In Israel, IT with highly allergenic pollens such as Pj frequently causes systemic reactions, even during the maintenance phase of treatment. In such cases, the reduction of IT dosage should be more than 50% during the pollen season, and a waiting period of 1 h should also be considered. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| buildup phase Kessel, A verfasserin aut Blant, A verfasserin aut Golan, TD oth In Allergy Oxford : Blackwell Munksgaard, 1978 54(1999), 6, Seite 0 Online-Ressource (DE-627)NLEJ243926979 (DE-600)2003114-2 1398-9995 nnns volume:54 year:1999 number:6 pages:0 http://dx.doi.org/10.1034/j.1398-9995.1999.t01-1-00094.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 54 1999 6 0 |
| allfieldsGer |
10.1034/j.1398-9995.1999.t01-1-00094.x doi (DE-627)NLEJ242307450 DE-627 ger DE-627 rakwb Toubi, E verfasserin aut Follow-up after systemic adverse reactions of immunotherapy Copenhagen Munksgaard International Publishers 1999 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Out of 280 immunotherapy (IT)-treated patients in our allergy clinic, 37 (13%) developed systemic adverse reactions. Parietaria judaica (Pj) extract, a highly allergenic pollen in northern Israel, was part of the IT regimen in 46% of treated patients who developed systemic adverse reactions. Twenty-six (70%) of systemic adverse reactions occurred during the buildup phase, whereas 11 (30%) occurred in the maintenance phase of treatment. Mild systemic reactions developed in 15/37 (40%), moderate in 20/37 (54%), and severe in 2/37 (5%) of patients. In 22/37 (59% of our IT-treated patients, adverse reactions developed within 30 min after injection. Among these were the two patients with severe systemic reactions. In 19%, moderate adverse reactions appeared at 30–60 min; in 22%, mild to moderate reactions appeared after 1–2 h. Our study concludes that severe systemic reactions to IT usually appear within 30 min after injection. In Israel, IT with highly allergenic pollens such as Pj frequently causes systemic reactions, even during the maintenance phase of treatment. In such cases, the reduction of IT dosage should be more than 50% during the pollen season, and a waiting period of 1 h should also be considered. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| buildup phase Kessel, A verfasserin aut Blant, A verfasserin aut Golan, TD oth In Allergy Oxford : Blackwell Munksgaard, 1978 54(1999), 6, Seite 0 Online-Ressource (DE-627)NLEJ243926979 (DE-600)2003114-2 1398-9995 nnns volume:54 year:1999 number:6 pages:0 http://dx.doi.org/10.1034/j.1398-9995.1999.t01-1-00094.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 54 1999 6 0 |
| allfieldsSound |
10.1034/j.1398-9995.1999.t01-1-00094.x doi (DE-627)NLEJ242307450 DE-627 ger DE-627 rakwb Toubi, E verfasserin aut Follow-up after systemic adverse reactions of immunotherapy Copenhagen Munksgaard International Publishers 1999 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Out of 280 immunotherapy (IT)-treated patients in our allergy clinic, 37 (13%) developed systemic adverse reactions. Parietaria judaica (Pj) extract, a highly allergenic pollen in northern Israel, was part of the IT regimen in 46% of treated patients who developed systemic adverse reactions. Twenty-six (70%) of systemic adverse reactions occurred during the buildup phase, whereas 11 (30%) occurred in the maintenance phase of treatment. Mild systemic reactions developed in 15/37 (40%), moderate in 20/37 (54%), and severe in 2/37 (5%) of patients. In 22/37 (59% of our IT-treated patients, adverse reactions developed within 30 min after injection. Among these were the two patients with severe systemic reactions. In 19%, moderate adverse reactions appeared at 30–60 min; in 22%, mild to moderate reactions appeared after 1–2 h. Our study concludes that severe systemic reactions to IT usually appear within 30 min after injection. In Israel, IT with highly allergenic pollens such as Pj frequently causes systemic reactions, even during the maintenance phase of treatment. In such cases, the reduction of IT dosage should be more than 50% during the pollen season, and a waiting period of 1 h should also be considered. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| buildup phase Kessel, A verfasserin aut Blant, A verfasserin aut Golan, TD oth In Allergy Oxford : Blackwell Munksgaard, 1978 54(1999), 6, Seite 0 Online-Ressource (DE-627)NLEJ243926979 (DE-600)2003114-2 1398-9995 nnns volume:54 year:1999 number:6 pages:0 http://dx.doi.org/10.1034/j.1398-9995.1999.t01-1-00094.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 54 1999 6 0 |
| source |
In Allergy 54(1999), 6, Seite 0 volume:54 year:1999 number:6 pages:0 |
| sourceStr |
In Allergy 54(1999), 6, Seite 0 volume:54 year:1999 number:6 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
buildup phase |
| isfreeaccess_bool |
false |
| container_title |
Allergy |
| authorswithroles_txt_mv |
Toubi, E @@aut@@ Kessel, A @@aut@@ Blant, A @@aut@@ Golan, TD @@oth@@ |
| publishDateDaySort_date |
1999-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243926979 |
| id |
NLEJ242307450 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242307450</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707153117.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s1999 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1034/j.1398-9995.1999.t01-1-00094.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242307450</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Toubi, E</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Follow-up after systemic adverse reactions of immunotherapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Copenhagen</subfield><subfield code="b">Munksgaard International Publishers</subfield><subfield code="c">1999</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Out of 280 immunotherapy (IT)-treated patients in our allergy clinic, 37 (13%) developed systemic adverse reactions. Parietaria judaica (Pj) extract, a highly allergenic pollen in northern Israel, was part of the IT regimen in 46% of treated patients who developed systemic adverse reactions. Twenty-six (70%) of systemic adverse reactions occurred during the buildup phase, whereas 11 (30%) occurred in the maintenance phase of treatment. Mild systemic reactions developed in 15/37 (40%), moderate in 20/37 (54%), and severe in 2/37 (5%) of patients. In 22/37 (59% of our IT-treated patients, adverse reactions developed within 30 min after injection. Among these were the two patients with severe systemic reactions. In 19%, moderate adverse reactions appeared at 30–60 min; in 22%, mild to moderate reactions appeared after 1–2 h. Our study concludes that severe systemic reactions to IT usually appear within 30 min after injection. In Israel, IT with highly allergenic pollens such as Pj frequently causes systemic reactions, even during the maintenance phase of treatment. In such cases, the reduction of IT dosage should be more than 50% during the pollen season, and a waiting period of 1 h should also be considered.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2002</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2002||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">buildup phase</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kessel, A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Blant, A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Golan, TD</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Allergy</subfield><subfield code="d">Oxford : Blackwell Munksgaard, 1978</subfield><subfield code="g">54(1999), 6, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926979</subfield><subfield code="w">(DE-600)2003114-2</subfield><subfield code="x">1398-9995</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:54</subfield><subfield code="g">year:1999</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1034/j.1398-9995.1999.t01-1-00094.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">54</subfield><subfield code="j">1999</subfield><subfield code="e">6</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
Toubi, E |
| spellingShingle |
Toubi, E misc buildup phase Follow-up after systemic adverse reactions of immunotherapy |
| authorStr |
Toubi, E |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243926979 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Copenhagen |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1398-9995 |
| topic_title |
Follow-up after systemic adverse reactions of immunotherapy buildup phase |
| publisher |
Munksgaard International Publishers |
| publisherStr |
Munksgaard International Publishers |
| topic |
misc buildup phase |
| topic_unstemmed |
misc buildup phase |
| topic_browse |
misc buildup phase |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
t g tg |
| hierarchy_parent_title |
Allergy |
| hierarchy_parent_id |
NLEJ243926979 |
| hierarchy_top_title |
Allergy |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243926979 (DE-600)2003114-2 |
| title |
Follow-up after systemic adverse reactions of immunotherapy |
| ctrlnum |
(DE-627)NLEJ242307450 |
| title_full |
Follow-up after systemic adverse reactions of immunotherapy |
| author_sort |
Toubi, E |
| journal |
Allergy |
| journalStr |
Allergy |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1999 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Toubi, E Kessel, A Blant, A |
| container_volume |
54 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
Toubi, E |
| doi_str_mv |
10.1034/j.1398-9995.1999.t01-1-00094.x |
| author2-role |
verfasserin |
| title_sort |
follow-up after systemic adverse reactions of immunotherapy |
| title_auth |
Follow-up after systemic adverse reactions of immunotherapy |
| abstract |
Out of 280 immunotherapy (IT)-treated patients in our allergy clinic, 37 (13%) developed systemic adverse reactions. Parietaria judaica (Pj) extract, a highly allergenic pollen in northern Israel, was part of the IT regimen in 46% of treated patients who developed systemic adverse reactions. Twenty-six (70%) of systemic adverse reactions occurred during the buildup phase, whereas 11 (30%) occurred in the maintenance phase of treatment. Mild systemic reactions developed in 15/37 (40%), moderate in 20/37 (54%), and severe in 2/37 (5%) of patients. In 22/37 (59% of our IT-treated patients, adverse reactions developed within 30 min after injection. Among these were the two patients with severe systemic reactions. In 19%, moderate adverse reactions appeared at 30–60 min; in 22%, mild to moderate reactions appeared after 1–2 h. Our study concludes that severe systemic reactions to IT usually appear within 30 min after injection. In Israel, IT with highly allergenic pollens such as Pj frequently causes systemic reactions, even during the maintenance phase of treatment. In such cases, the reduction of IT dosage should be more than 50% during the pollen season, and a waiting period of 1 h should also be considered. |
| abstractGer |
Out of 280 immunotherapy (IT)-treated patients in our allergy clinic, 37 (13%) developed systemic adverse reactions. Parietaria judaica (Pj) extract, a highly allergenic pollen in northern Israel, was part of the IT regimen in 46% of treated patients who developed systemic adverse reactions. Twenty-six (70%) of systemic adverse reactions occurred during the buildup phase, whereas 11 (30%) occurred in the maintenance phase of treatment. Mild systemic reactions developed in 15/37 (40%), moderate in 20/37 (54%), and severe in 2/37 (5%) of patients. In 22/37 (59% of our IT-treated patients, adverse reactions developed within 30 min after injection. Among these were the two patients with severe systemic reactions. In 19%, moderate adverse reactions appeared at 30–60 min; in 22%, mild to moderate reactions appeared after 1–2 h. Our study concludes that severe systemic reactions to IT usually appear within 30 min after injection. In Israel, IT with highly allergenic pollens such as Pj frequently causes systemic reactions, even during the maintenance phase of treatment. In such cases, the reduction of IT dosage should be more than 50% during the pollen season, and a waiting period of 1 h should also be considered. |
| abstract_unstemmed |
Out of 280 immunotherapy (IT)-treated patients in our allergy clinic, 37 (13%) developed systemic adverse reactions. Parietaria judaica (Pj) extract, a highly allergenic pollen in northern Israel, was part of the IT regimen in 46% of treated patients who developed systemic adverse reactions. Twenty-six (70%) of systemic adverse reactions occurred during the buildup phase, whereas 11 (30%) occurred in the maintenance phase of treatment. Mild systemic reactions developed in 15/37 (40%), moderate in 20/37 (54%), and severe in 2/37 (5%) of patients. In 22/37 (59% of our IT-treated patients, adverse reactions developed within 30 min after injection. Among these were the two patients with severe systemic reactions. In 19%, moderate adverse reactions appeared at 30–60 min; in 22%, mild to moderate reactions appeared after 1–2 h. Our study concludes that severe systemic reactions to IT usually appear within 30 min after injection. In Israel, IT with highly allergenic pollens such as Pj frequently causes systemic reactions, even during the maintenance phase of treatment. In such cases, the reduction of IT dosage should be more than 50% during the pollen season, and a waiting period of 1 h should also be considered. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
6 |
| title_short |
Follow-up after systemic adverse reactions of immunotherapy |
| url |
http://dx.doi.org/10.1034/j.1398-9995.1999.t01-1-00094.x |
| remote_bool |
true |
| author2 |
Kessel, A Blant, A Golan, TD |
| author2Str |
Kessel, A Blant, A Golan, TD |
| ppnlink |
NLEJ243926979 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1034/j.1398-9995.1999.t01-1-00094.x |
| up_date |
2024-07-06T01:32:34.475Z |
| _version_ |
1803791425314226177 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242307450</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707153117.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s1999 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1034/j.1398-9995.1999.t01-1-00094.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242307450</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Toubi, E</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Follow-up after systemic adverse reactions of immunotherapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Copenhagen</subfield><subfield code="b">Munksgaard International Publishers</subfield><subfield code="c">1999</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Out of 280 immunotherapy (IT)-treated patients in our allergy clinic, 37 (13%) developed systemic adverse reactions. Parietaria judaica (Pj) extract, a highly allergenic pollen in northern Israel, was part of the IT regimen in 46% of treated patients who developed systemic adverse reactions. Twenty-six (70%) of systemic adverse reactions occurred during the buildup phase, whereas 11 (30%) occurred in the maintenance phase of treatment. Mild systemic reactions developed in 15/37 (40%), moderate in 20/37 (54%), and severe in 2/37 (5%) of patients. In 22/37 (59% of our IT-treated patients, adverse reactions developed within 30 min after injection. Among these were the two patients with severe systemic reactions. In 19%, moderate adverse reactions appeared at 30–60 min; in 22%, mild to moderate reactions appeared after 1–2 h. Our study concludes that severe systemic reactions to IT usually appear within 30 min after injection. In Israel, IT with highly allergenic pollens such as Pj frequently causes systemic reactions, even during the maintenance phase of treatment. In such cases, the reduction of IT dosage should be more than 50% during the pollen season, and a waiting period of 1 h should also be considered.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2002</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2002||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">buildup phase</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kessel, A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Blant, A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Golan, TD</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Allergy</subfield><subfield code="d">Oxford : Blackwell Munksgaard, 1978</subfield><subfield code="g">54(1999), 6, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926979</subfield><subfield code="w">(DE-600)2003114-2</subfield><subfield code="x">1398-9995</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:54</subfield><subfield code="g">year:1999</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1034/j.1398-9995.1999.t01-1-00094.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">54</subfield><subfield code="j">1999</subfield><subfield code="e">6</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.3998547 |